Table 2.
Incidence of sustained viral load suppression, persistent viremia, viral rebound, and new suppression among people living with human immunodeficiency virus in Rwanda
| Characteristics |
Sustained VLS
|
Persistent viremia
|
Viral rebound
|
Newly suppressed
|
||||
|
n/N
|
%
|
n/N
|
%
|
n/N
|
%
|
n/N
|
%
|
|
| Overall | 829/973 | 85.2 | 42/973 | 4.3 | 45/973 | 4.6 | 57/973 | 5.9 |
| Age, year | ||||||||
| 18-24 | 21/27 | 77.8 | 1/27 | 3.7 | 4/27 | 14.8 | 1/27 | 3.7 |
| 25-34 | 271/314 | 86.3 | 10/314 | 3.2 | 15/314 | 4.8 | 18/314 | 5.7 |
| 35-44 | 332/405 | 82.2 | 22/332 | 5.4 | 21/405 | 5.2 | 30/405 | 7.4 |
| 45-54 | 130/137 | 94.9 | 3/137 | 2.2 | 3/137 | 2.2 | 1/137 | 0.7 |
| ≥ 55 | 75/90 | 83.3 | 6/90 | 6.7 | 2/90 | 2.2 | 7/90 | 7.8 |
| Gender | ||||||||
| Female | 539/622 | 86.7 | 21/622 | 3.4 | 26/622 | 4.2 | 36/622 | 5.8 |
| Male | 288/349 | 82.5 | 21/349 | 6.0 | 19/349 | 5.4 | 21/349 | 6.0 |
| Education | ||||||||
| No education | 341/423 | 80.6 | 27/423 | 6.4 | 24/423 | 5.7 | 31/423 | 7.3 |
| ≥ Primary | 465/523 | 88.9 | 14/523 | 2.7 | 19/523 | 3.6 | 25/523 | 4.8 |
| HIV status disclosed | ||||||||
| No | 348/406 | 85.7 | 13/406 | 3.2 | 19/406 | 4.7 | 26/406 | 6.4 |
| Yes | 475/561 | 84.7 | 29/561 | 5.2 | 26/561 | 4.6 | 31/561 | 5.5 |
| Adherence | ||||||||
| < 90% | 175/217 | 80.6 | 17/217 | 7.8 | 14/217 | 6.5 | 11/217 | 5.1 |
| ≥ 90% | 562/648 | 86.7 | 20/648 | 3.1 | 26/648 | 4.0 | 40/648 | 6.2 |
| Advance HIV disease | ||||||||
| Yes | 122/157 | 77.7 | 14/157 | 8.9 | 12/157 | 7.6 | 9/157 | 5.7 |
| No | 585/671 | 87.2 | 18/671 | 2.7 | 28/671 | 4.2 | 40/671 | 6.0 |
| Timing of ART initiation | ||||||||
| Before treat all | 389/451 | 86.3 | 24/451 | 5.3 | 17/451 | 3.8 | 21/451 | 4.7 |
| After treat all | 433/513 | 84.4 | 18/513 | 3.5 | 27/513 | 5.3 | 35/513 | 6.8 |
HIV: Human immunodeficiency virus; VLS: Viral load suppression; ART: Antiretroviral therapy.